Phase 2 N=131 Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Clinical Remission Response Rate at Week 12 — 14.8; 16.3 Percentage of Participants — p=0.5935
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=91 Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects
Healthy
Primary: Number of Participants With Drug-related Adverse Events (AEs) — 3; 1; 4; 1 Participants
Phase 2 N=206 Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Clostridium Difficile Infection Recurrence
Primary: Number of Participants With Absence of Recurrence Through Week 8 Based on Adjudication — 76; 59 Participants — p=0.0488
N/A N=167 Clinical Comparison of Two Daily Disposable Contact Lenses
Refractive Errors
Primary: Least Squares Mean Distance VA (logMAR) With Study Lenses — -0.119; -0.122 logMAR
N/A N=436 Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: Clinical Global Impressions - Improvement Scale (CGI-I; Patient Version) — 68.1; 64.6; 46.7; 64.0 percentage of treatment responders
N/A N=19 iTBS Study for Depression (Randomized)
Executive Dysfunction · Depression
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Scores From Baseline to the End of the Intervention — 10.25; 13.33 score on a scale
N/A N=208 Transdisciplinary Versus Usual Care for Type1 Diabetes in Adolescence
Type 1 Diabetes Mellitus
Primary: Glycosylated Hemoglobin (HbA1c) — 8.59; 9.02; 8.71; 9.03 percentage of glycosylated hemoglobin — p=0.895
N/A N=964 St. Joe's Invitation Effectiveness Study
Cervical Cancer Screening
Primary: Percentage of Cervical Cancer Screening — 40; 95 Participants
Phase 2 N=25 A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Overall Response Rate — 0; 2; 3; 19 Participants
Phase 3 N=931 A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease
Primary: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission — 24.6; 45.2; 41.6 percentage of participants — p=<0.001
Phase 3 N=882 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Triple Negative Breast Cancer (TNBC)
Primary: Part 1: Percentage of Participants Who Experienced an Adverse Event (AE) - All Participants — 100.0; 100.0; 100.0 Percentage of Participants
N/A N=410 Effect of Sport Education in University Required PE on Students' Perceived Physical Literacy and Physical Activity Level
Physical Activity · Motivation
Primary: Self-report Physical Activity Levels — 2114.83; 2245.51; 3334.41; 3052.78 MET-minutes/week
Phase 2 N=247 miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome
Major Depressive Disorder
Primary: Beck Scale for Suicide Ideation (BSS) — 9.09; 8.46; 1.9 units on a scale
Phase 4 N=66 Progesterone and Brain Imaging Study
Nicotine Dependence · Nicotine Withdrawal
Primary: GABA Pre and Post Progesterone Administration (Dorsal Anterior Cingulate Cortex [DACC]) — 1.23; 1.17; 1.28; 1.24 mg/dl
Phase 2 N=67 Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Primary: Number of Patients With Gene Alterations — 7; 4; 7; 7 Participants